The Official Journal of EuroPCR and the European Association of Percutaneous Coronary Interventions (EAPCI)
Moxy® drug-coated balloon: a novel device for the treatment of coronary and peripheral vascular disease
EuroIntervention 2011;7:274-277 published online ahead of print May 2011. DOI: 10.4244/EIJV7I2A44
Juan Luis Gutierrez-Chico, MD, PhD; Evelyn Regar, MD, PhD; Robert-Jan van Geuns, MD, PhD; Scot Garg, MD, PhD; Carl Schultz, MD, PhD; Nicolas van Mieghem, MD; Henricus Duckers, MD, PhD; Patrick W Serruys*, MD, PhD, FESC
Interventional Cardiology Department, Thoraxcenter, Erasmus MC, Rotterdam, The Netherlands
The Moxy drug-coated PTCA/PTA balloon (Lutonix, Inc. Maple Grove, MN, USA) is a paclitaxel-coated balloon with a hydrophilic carrier to optimize the drug release onto the vessel wall. It represents an interesting alternative to drug-eluting stent (DES) for the percutaneous treatment of in-stent restenosis, de novo coronary lesions or peripheral artery disease.
Adoption of DES has reduced coronary restenosis rates to 7.9-8.9% at nine months1-3, but this benefit is compromised by a higher incidence of late and very late stent thrombosis4-8. The polymer component of DES may contribute to inflammation of the ...